Travere Therapeutics(NASDAQ) TVTX

Travere Therapeutics, Inc. makes medicines for people with rare diseases. These treatments help patients manage serious kidney and metabolic conditions. The company focuses on health problems that have few other options.

What Does Travere Make?

• FILSPARI (sparsentan): Oral, once-daily medicine approved to slow kidney function decline in adults with primary IgA nephropathy (IgAN); generated $246.2 million in net product sales for the six-month period ended June 30, 2026.
• FILSPARI (FSGS): First FDA-approved treatment to reduce protein in the urine for patients with focal segmental glomerulosclerosis (FSGS) who are at risk of kidney failure.
• Thiola and Thiola EC: Tablets used to treat cystinuria, a genetic disorder causing recurring kidney stones; accounted for $39.6 million in net product sales for the six-month period ended June 30, 2026.
• Pegtibatinase: Investigational enzyme replacement therapy in Phase 3 clinical trials for the treatment of classical homocystinuria (HCU), a metabolic disorder.
• Civorebrutinib: Pipeline drug candidate designed to block a specific protein called Bruton’s tyrosine kinase (BTK) to treat immune-mediated kidney diseases.

Moving Into New Markets

• Partnered with CSL Vifor in Sept. 2021 to commercialize FILSPARI in Europe, where it has since received standard marketing authorization.
• Sold the bile acid product portfolio to Mirum in Aug. 2023, receiving a $210 million upfront payment and a $25 million milestone in April 2026.
• Licensed sparsentan rights for Japan and other Asian countries to Renalys Pharma in Jan. 2024, a business later acquired by Chugai.
• Restarted the Phase 3 HARMONY Study for pegtibatinase in the first quarter of 2026 after improving the drug's manufacturing scale-up process.
• Signed a June 2026 agreement with Everest Medicines to develop civorebrutinib in the United States and other global territories.

How the Company Competes

Travere uses specialized Orphan Drug designations to secure exclusive market rights for its rare disease treatments. The company employs a dedicated field force to help doctors identify and manage patients with complex kidney conditions.

Tracking the Recent Numbers

• Total revenue reached $296.8 million for the six-month period ended June 30, 2026, up from $196.2 million in the same period of 2025.
• Research and development expenses rose to $117.4 million in the first half of 2026 to support late-stage clinical trials.
• The company held $117.7 million in cash and $371.4 million in marketable debt securities as of June 30, 2026.
• Selling, general and administrative expenses grew to $176.4 million in the first six months of 2026 to support new product launches.
• Market cap reached $5.3 billion in the second quarter of 2026, a 303.4% increase from the previous year.

Bottom Line

Travere has evolved into a kidney-focused biopharmaceutical company led by the commercial growth of its flagship therapy, FILSPARI. By licensing international rights and reinvesting in its metabolic pipeline, the firm continues to expand its reach in the rare disease market.